Yes, exosomes have shown great potential as biomarkers in cancer diagnosis and prognosis. Because they carry specific molecular signatures reflective of their cell of origin, exosomal contents can be analyzed to detect cancer at an early stage, monitor disease progression, and evaluate the response to treatment. Liquid biopsy, which involves the analysis of exosomes in bodily fluids like blood and urine, is a minimally invasive method that holds promise for personalized cancer management.
